Rosman Yossi, Elmalak Mohamad, Meir-Shafrir Keren, Lachover-Roth Idit, Cohen-Engler Anat, Confino-Cohen Ronit
Allergy and Clinical Immunology Unit, Meir Medical Center, Israel.
Sackler School of Medicine, Tel-Aviv University, Israel.
World Allergy Organ J. 2021 Jan 22;14(2):100506. doi: 10.1016/j.waojou.2020.100506. eCollection 2021 Feb.
Mislabeling patients as allergic to beta lactams poses an increased risk of morbidity, healthcare costs, and even mortality. This study aimed to define the accuracy of medical history, taken by a specialist, in diagnosing immediate reaction to beta lactams.
All patients labeled as allergic to beta lactam were interviewed by a specialist in allergy and clinical immunology and defined as suspected of having a history of immediate or non-immediate reaction. When indicated, skin tests to major and minor determinants and oral graded challenge to the culprit drug were performed.
A total of 909 patients were evaluated. A total of 798 (87.7%) were labeled as allergic to penicillin. In 108 (11.9%) cases, the allergist suspected an immediate reaction based on clinical history. Skin test or challenge proven diagnosis of IgE-mediated allergy to beta lactam were significantly more prevalent in the group with an allergist's suspicion of an immediate allergy (23.1% vs. 5%, p < 0.01). The sensitivity and negative predictive values of an anamnesis of immediate reaction were high (0.9 and 0.95, respectively), but the specificity and positive predictive value were low (0.37 and 0.23, respectively).
Medical history taken by an allergist can exclude immediate hypersensitivity reaction, but it is not specific enough to confirm the diagnosis. Skin testing and graded challenge in suspected cases of immediate hypersensitivity reaction are indicated.
将患者错误标记为对β-内酰胺类药物过敏会增加发病风险、医疗成本,甚至导致死亡。本研究旨在确定专科医生获取的病史在诊断β-内酰胺类药物速发型反应方面的准确性。
所有被标记为对β-内酰胺类药物过敏的患者均由过敏与临床免疫专科医生进行访谈,并被定义为疑似有速发型或非速发型反应病史。必要时,进行主要和次要决定簇的皮肤试验以及对可疑药物的口服分级激发试验。
共评估了909例患者。共有798例(87.7%)被标记为对青霉素过敏。在108例(11.9%)病例中,过敏专科医生根据临床病史怀疑为速发型反应。在过敏专科医生怀疑为速发型过敏的组中,皮肤试验或激发试验证实的IgE介导的β-内酰胺类药物过敏明显更为常见(23.1%对5%,p<0.01)。速发型反应病史的敏感性和阴性预测值较高(分别为0.9和0.95),但特异性和阳性预测值较低(分别为0.37和0.23)。
过敏专科医生获取的病史可以排除速发型超敏反应,但特异性不足以确诊。对于疑似速发型超敏反应的病例,建议进行皮肤试验和分级激发试验。